Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
In a message to constituents, Congressman John Garamendi is taking issue with statements earlier this month by House Speaker Mike Johnson regarding wildfire relief funds for California in the wake ...
Photo shows Rutgers Full-Time MBA student Abha Mehta sitting on steps inside Rutgers Business School in Newark. The Full-Time ...
"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...
Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...
Valley Vital operates infusion therapy pharmacies across four regions in Virginia and West Virginia, offering comprehensive ...
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
Senators spent three hours wrestling with some familiar health care topics on Wednesday, including prior authorization and ...
Johnson & Johnson reported higher-than-expected fourth-quarter revenues, driven by strong cancer drug sales, amidst its ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...